As GlaxoSmithKline ( NYSE: GSK ) defended Avandia before an FDA advisory panel yesterday, its lawyers were making sure that defense doesn’t move to a courtroom. In some 10,000 lawsuits, that is. The company agreed to pay about $460 million to settle those suits, which amount to a majority…
A union pension fund is suing Pfizer ( NYSE: PFE ) and its board, alleging that directors ignored signs that the drugmaker was playing fast and loose with off-label marketing. The fund blames the board, in part, for that record-setting $2.3 billion marketing settlement with the Justice Department. “The…
Eli Lilly plans to cut 170 manufacturing and quality-control jobs this year, most of them in Indianapolis, as part of its ongoing downsizing efforts. Report
The drug industry in the U.S. has a new lead lobbyist. PhRMA has chosen John Castellani ( photo )
You know what today is: FDA’s expert advisors are meeting to determine the fate of GlaxoSmithKline’s diabetes remedy Avandia . The agency delivered 700 pages of documents for the committee’s perusal ahead of time. But should they have more material to read? Lawyers for plaintiffs who allege they’ve been…
GAITHERSBURG, MD — Today is the day–the long awaited joint meeting of the FDA’s Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees
Consumers are accusing Johnson & Johnson ( NYSE: JNJ )
The U.S. Food and Drug Administration (FDA) posted a comprehensive review conducted by GlaxoSmithKline (GSK) of the cardiovascular safety data on Avandia® (rosiglitazone maleate).
Original Source of Data support Avandia (rosiglitazone maleate) cardiovascular safety profile
Increasingly, the FDA wants drugmakers to give equal billing to the possible risks of taking drugs, not just rattle them off in the last few seconds of a TV commercial or bury them deep in print. Report
Original Source of Equal time for risk info in ads, FDA says…